Pharmaceutical

Oxford Cannabinoid Technologies sees changes across the board

Richard Guy Hathaway has been appointed as non-executive director, and Julie Pomeroy has been appointed non-executive chair.

Oxford Cannabinoid Technologies sees changes across the board
Home / Oxford Cannabinoid Technologies sees changes across the board

Estimated reading time: 2 minutes

Oxford Cannabinoid technologies Holdings (OCTP) has announced changes to its board.

The company, which develops prescription cannabinoid medicines for approval, has appointed Hathaway as non-executive director, and Pomeroy as non-executive chair.

OCTP chief executive, John Lucas, commented: “We are delighted to welcome Richard Hathaway to the board as our new non-executive director, where his own extensive financial and corporate experience will be of great benefit to the company.

Read more: Further drug development agreement for Oxford Cannabinoid Technologies

“The Board is very grateful to Julie for agreeing to step up to the role of company chair. Her PLC experience both in an executive and non-executive capacity will be invaluable as the business enters a key stage in its development, preparing to move into Phase I clinical trials for our lead candidate OCT461201 and our inhaled cannabinoids programme, OCT130401, in Q1 2023 and Q4 2022, respectively.

“At the same time, we thank Neil as incumbent chair, for his knowledge and guidance and look forward to continuing to work with him in his capacity as non-executive director.”

Pomeroy will assume the role of non-executive chair with effect from 11 February 2022, at which time the current executive chairman, Mr Neil Mahapatra will step down but remain on the board as a non-executive director.

Read more: Oxford Cannabinoid Technologies sees positive progression

Hathaway has been appointed as a representative of Imperial Brands Ventures Limited, with effect from 1 February 2022. Imperial, a 10.87 per cent shareholder of OCTP, nominated Mr Hathaway as its representative following the resignation of Bishrut Mukherjee from Imperial in September 2021.

Hathaway is the Corporate Development Director at Imperial Brands plc, the ultimate holding company of Imperial where he is responsible for leading M&A activity and other strategic initiatives and projects across the business

Bishrut Mukherjee remains on the Board of OCTP in his capacity as non-executive director.

[activecampaign form=31]

Topicscannabis industry newsleadershipmedical cannabis

Stephanie Price

Stephanie is a journalist for Business of Cannabis, writing about science, research, policy and industry developments in cannabis, CBD and psychedelics. In 2013 Stephanie gained her BA in English and Media, focusing on journalism and propaganda, where her magazine 'Game Theory' focused on developments and disruptors over the coming decade including cannabis, psychedelics, blockchain/crypto and free speech. In 2015 Stephanie received her National Council for the Training of Journalists (NCTJ) diploma whilst working as a reporter in North Wales. Stephanie has a specialism in Medical Cannabis: The Health Effects of THC and CBD through the University of Colorado, and a certificate from the Medical Cannabis Clinicians Society on "Medical Cannabis Explained".

More from Stephanie

Spotted an error, or have a tip? Contact the newsroom.

Up next · Pharmaceutical

Brains Bioceutical To List On NASDAQ Via SPAC At US$750m Valuation

Ben Stevens · 6 November 2026

More